{"disease":{"id":"bulimia-atypical","name":"bulimia atypical"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04862247","title":"Online Relapse Prevention Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"University of Louisville","has_results":false},{"nct_id":"NCT04661410","title":"Reward Re-Training: A New Treatment to Address Reward Imbalance During the COVID-19 Pandemic","phase":"NA","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Drexel University","has_results":true},{"nct_id":"NCT05753410","title":"App-Based Mindfulness Training for Individuals With Anorexia Nervosa and Bulimia Nervosa","phase":"NA","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Yeshiva University","has_results":true},{"nct_id":"NCT05073679","title":"Oral Naltrexone In Pediatric Eating Disorders","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Rosemary Claire Roden","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}